Samaritan begins second phase 2 study of anti-viral SP01A for HIV

By Lisa Kerner

Erie, Pa., March 9 - Samaritan Pharmaceuticals Inc. said it is starting a second phase 2 monotherapy trial of its lead oral entry inhibitor anti-viral agent, SP01A, in treatment-experienced HIV-infected patients.

"We have completed enrollment for our first monotherapy trial and the start of this second trial means we have cleared another important milestone in SP01A's development path," chief drug development officer Thomas Lang said in a company news release.

The phase 2 trial is a multi-center, double-blind, randomized, placebo-controlled study designed to accrue treatment-experienced HIV patients that are failing their current anti-viral therapy, Samaritan said.

Study participants will be entered into a two-week washout phase followed by 28 days of monotherapy treatment with SP01A.

The primary analysis for the study is the reduction in viral load in SP01A active arms and a placebo arm, as measured from baseline to study end, the company said.

Las Vegas-based Samaritan discovers, develops and commercializes therapeutics for AIDS, Alzheimer's, cancer and heart disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.